P03951 (FA11_HUMAN) Homo sapiens (Human)
Coagulation factor XI UniProtKBInterProSTRINGInteractive Modelling
625 aa; Sequence (Fasta) ; (Isoform 2)
It is possible new templates exist for this target since these models were created.
Available Structures
114 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| human recombinant coagulation FXI in complex with a peptide derived from human high molecular weigh… |
Heteromer P01042; | 100.0 | 3×NAG; | |||
| Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes |
Heteromer P01042; | 100 | 2×NAG; 3×SO4; | |||
| Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}a… |
Heteromer | 99.16 | 1×39D; 1×SO4; 8×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazi… |
Heteromer | 99.16 | 1×NRJ; 1×SO4; 12×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazo… |
Heteromer | 99.16 | 1×3Y5; 1×SO4; 11×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-y… |
Heteromer | 99.16 | 1×9FA; 2×SO4; 12×EDO; | |||
| Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R |
Heteromer P23827; | 100 | 1×NAG; | |||
| Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin |
Heteromer P23827; | 99.16 | ||||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease … |
Heteromer P05067; | 98.73 | ||||
| Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP) |
Heteromer P23827; | 99.16 | 2×NA; | |||
| FXIa antibody complex |
Heteromer | 98.31 | 4×SO4; 9×GOL; 3×CO; 5×PO4; | |||
| Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting th… |
Heteromer | 99.56 | 3×SO4; 1×DMS; | |||
| COAGULATION FACTOR XI CATALYTIC DOMAIN IN COMPLEX WITH FAB-PORTION OF MAA868 |
Heteromer | 99.56 | ||||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | homo-3-mer | 97.9 | 3×MVN; 24×SO4; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | homo-3-mer | 98.29 | 12×GOL; 3×J4X; 12×SO4; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | homo-3-mer | 98.31 | 3×OTJ; 9×SO4; | |||
| Allosteric activation of human prekallikrein by apple domain disc rotation | homo-2-mer | 100.0 | 2×NAG; 10×CL; 2×PEG; 4×NAG; | |||
| Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Brid… | homo-2-mer | 99.16 | 2×ACN; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XIa in Complex with Double Bridged … | homo-2-mer | 99.16 | 3×NH4; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phe… | homo-2-mer | 99.16 | 1×QLD; 2×SO4; 13×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1… | homo-2-mer | 99.16 | 1×QEV; 1×SO4; 9×EDO; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | homo-2-mer | 98.32 | 2×OTW; 12×SO4; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | homo-2-mer | 98.32 | 2×0TU; 14×SO4; | |||
| Solution Structure of the A4 Domain of Blood Coagulation Factor XI | homo-2-mer | 100 | ||||
| FXI Apple 4 domain loop-out conformation | homo-2-mer | 100 | ||||
| Human Plasma Coagulation Factor XI in complex with peptide P39 | monomer | 100.0 | 1×NAG; 3×NAG; | |||
| Human Plasma Coagulation FXI with peptide LP2 | monomer | 100.0 | 3×NAG; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-Y… | monomer | 99.16 | 1×7DL; 1×SO4; 15×EDO; | |||
| Crystal structure of Factor XIa in complex with Clavatadine A | monomer | 99.16 | 1×G0R; 1×BEN; 5×SO4; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S43… | monomer | 98.32 | 1×BEN; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | monomer | 98.32 | 2×GOL; 1×XJ8; 3×SO4; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | monomer | 98.32 | 2×GOL; 1×7P0; 4×SO4; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phe… | monomer | 99.16 | 1×QLJ; 2×SO4; 13×EDO; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-… | monomer | 98.32 | 2×SO4; 1×BCT; 1×421; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimido… | monomer | 98.32 | 1×SO4; 1×BCT; 1×709; | |||
| Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tet… | monomer | 99.16 | 1×4GR; 2×SO4; 9×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-O… | monomer | 99.16 | 1×SWP; 2×SO4; 12×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-… | monomer | 99.16 | 1×NR7; 1×SO4; 8×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-… | monomer | 99.16 | 1×5JM; 2×SO4; 9×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]c… | monomer | 99.16 | 1×5ST; 2×SO4; 5×EDO; | |||
| Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chlo… | monomer | 99.16 | 1×39F; 2×SO4; 7×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol… | monomer | 99.16 | 1×3Y4; 2×SO4; 9×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]et… | monomer | 99.16 | 1×7P0; 1×SO4; 10×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1… | monomer | 99.16 | 1×BUY; 1×SO4; 10×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-Y… | monomer | 99.16 | 1×7DS; 2×SO4; 11×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PH… | monomer | 99.16 | 1×7DK; 2×SO4; 10×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)ph… | monomer | 99.16 | 1×QLM; 2×SO4; 14×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phen… | monomer | 99.16 | 1×9EY; 2×SO4; 13×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p… | monomer | 99.16 | 1×9FD; 2×SO4; 15×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p… | monomer | 99.16 | 1×QLS; 2×SO4; 13×EDO; | |||
| Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroqui… | monomer | 99.16 | 1×4CE; 1×SO4; 5×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluora… | monomer | 99.16 | 1×BVJ; 1×SO4; 15×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H… | monomer | 99.16 | 1×QEY; 1×SO4; 11×EDO; | |||
| Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-p… | monomer | 100 | 1×1T6; 1×SO4; 2×EDO; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | monomer | 98.32 | 3×GOL; 1×R9B; 4×SO4; 1×CL; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indaz… | monomer | 99.16 | 1×5SS; 2×SO4; 7×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1… | monomer | 99.16 | 1×BVM; 1×SO4; 15×EDO; | |||
| Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E… | monomer | 99.16 | 1×EEJ; 1×SO4; 12×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)ph… | monomer | 99.16 | 1×9ZM; 1×SO4; 14×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazo… | monomer | 99.16 | 1×3Y3; 1×SO4; 9×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenz… | monomer | 99.16 | 1×9F1; 2×SO4; 8×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p… | monomer | 99.16 | 1×9F7; 1×SO4; 5×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-… | monomer | 99.16 | 1×3VM; 2×SO4; 2×EDO; | |||
| Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tet… | monomer | 99.16 | 1×4D5; 2×SO4; 7×EDO; | |||
| FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetr… | monomer | 99.16 | 1×BUV; 1×SO4; 3×EDO; | |||
| Factor XIA in complex with the inhibitor 3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetr… | monomer | 100 | 1×1T5; 3×SO4; | |||
| FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR Milvexian (BMS-986177), I… | monomer | 99.58 | 1×NAG; 1×YXG; | |||
| COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 2 | monomer | 99.58 | 1×QW0; 1×CIT; 4×GOL; | |||
| FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5… | monomer | 99.58 | 1×NAG; 1×5SU; | |||
| Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | monomer | 97.89 | 1×OTM; 1×SO4; | |||
| Factor XIa in Complex with Compound 2a | monomer | 99.58 | 1×OQ6; | |||
| Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine… | monomer | 98.73 | 1×BEN; 1×GSH; | |||
| Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ket… | monomer | 98.31 | 2×BCT; 1×SO4; 1×682; | |||
| Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylbo… | monomer | 98.31 | 2×SO4; 1×HDB; 1×TRS; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hyd… | monomer | 98.31 | 3×SO4; 1×427; | |||
| Factor XI complexed with a pyrimidinone inhibitor | monomer | 99.16 | 1×624; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino… | monomer | 98.31 | 2×SO4; 1×BCT; 1×632; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentano… | monomer | 98.31 | 1×SO4; 1×995; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic… | monomer | 98.31 | 1×SO4; 1×339; | |||
| Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-… | monomer | 98.31 | 6×SO4; 1×BCT; 1×412; | |||
| Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate | monomer | 99.16 | 3×SO4; 1×367; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo… | monomer | 98.31 | 2×SO4; 1×62A; | |||
| Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-… | monomer | 98.31 | 3×SO4; 1×368; 1×GOL; | |||
| Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-keto… | monomer | 99.14 | 1×SO4; 1×BUK; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1… | monomer | 98.31 | 2×SO4; 1×737; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-p… | monomer | 98.31 | 3×SO4; 1×716; | |||
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S43… | monomer | 98.73 | 1×BEN; 1×GSH; | |||
| Coagulation factor XI protease domain in complex with active site inhibitor | monomer | 99.15 | 3×SO4; 5×DMS; 1×NA; 1×J7B; | |||
| COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 34 | monomer | 99.58 | 1×QW6; 1×CIT; 1×TRS; | |||
| COAGULATION FACTOR XI CATALYTIC DOMAIN (C123S) IN COMPLEX WITH NVP-XIV936 | monomer | 99.58 | 1×QGS; | |||
| Coagulation factor XI protease domain in complex with active site inhibitor | monomer | 99.58 | 1×NW2; 3×SO4; 2×DMS; | |||
| Coagulation factor XI protease domain in complex with active site inhibitor | monomer | 99.58 | 3×SO4; 3×DMS; 1×NW5; | |||
| Factor XIa in Complex with Compound 2e | monomer | 99.58 | 1×OQO; 1×CIT; | |||
| Factor XIa in Complex with Compound 2j | monomer | 99.58 | 1×CIT; 1×OT7; | |||
| Factor XIa in Complex with Compound 2k | monomer | 99.58 | 1×CIT; 1×OTL; | |||
| Factor XIa in Complex with Compound 2g | monomer | 99.58 | 1×CIT; 1×ORF; | |||
| Factor XIa in complex with compound 7 | monomer | 99.58 | 1×CIT; 1×R2Y; | |||
| Human FXIa in complex with small molecule inhibitors. | monomer | 98.31 | 1×GOL; 1×IXA; 4×SO4; | |||
| Factor XIa in Complex with Compound 2f | monomer | 99.58 | 1×OR0; 1×CIT; | |||
| Factor XIa in Complex with Compound 2i | monomer | 99.58 | 1×CIT; 1×OSX; | |||
| Factor XIa in Complex with Compound 2h | monomer | 99.58 | 1×CIT; 1×ORU; | |||
| COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 3 | monomer | 99.58 | 1×QVO; 1×CIT; 2×GOL; | |||
| Factor XIa in complex with compound 11 | monomer | 99.58 | 2×FLC; 1×R3A; | |||
| Factor XIa in Complex with Compound 3f | monomer | 99.58 | 1×CIT; 1×OTX; | |||
| COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 1 | monomer | 99.57 | 1×GOL; 1×QVI; | |||
| Human FXIa in complex with small molecule inhibitors. | monomer | 98.31 | 3×GOL; 1×J1J; 3×SO4; | |||
| Factor XIa in Complex with Compound 2d | monomer | 99.58 | 1×OQI; 1×CIT; | |||
| Factor XIa in complex with a clorophenyl-tetrazole inhibitor | monomer | 99.58 | 1×CIT; 1×O58; | |||
| COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR Asundexian | monomer | 99.58 | 1×QV3; 1×CIT; | |||
| FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-amin… | monomer | 99.58 | 1×NAG; 1×3YU; 1×CIT; 1×GOL; | |||
| Human FXIa in complex with small molecule inhibitors. | monomer | 98.31 | 6×GOL; 1×E6U; 5×SO4; 1×TRS; | |||
| Benzothiazinone inhibitor in complex with FXIa | monomer | 99.58 | 1×CIT; 1×TRS; 1×O61; | |||
| Coagulation factor XI protease domain in complex with active site inhibitor | monomer | 99.58 | 1×NWE; | |||
| The crystal structure of FXIa serine protease domain in complex with benzamidine | monomer | 98.73 | 1×BEN; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6i58.1.A | monomer | 0.82 | 100.00 | |||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 6i58.1.A | monomer | 0.78 | 99.64 | |||